Huang, Wei http://orcid.org/0000-0003-2097-8148
Li, Hongyun
Kiselar, Janna
Fink, Stephen P.
Regmi, Sagar http://orcid.org/0000-0001-5104-6613
Day, Alexander
Yuan, Yiyuan
Chance, Mark
Ready, Joseph M. http://orcid.org/0000-0003-1305-9581
Markowitz, Sanford D. http://orcid.org/0000-0001-5369-5254
Taylor, Derek J. http://orcid.org/0000-0001-9932-1856
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (HSSN261200800001, R01 CA216863, U54 CA231649, R35 CA197442, P50 CA150964, R01 CA240993)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM116961, RM1 GM142002, RM1 GM142002, RM1 GM142002, R01 GM133841, U24 GM116789)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Welch Foundation (I-1612)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 14 June 2022
Accepted: 1 February 2023
First Online: 11 February 2023
Competing interests
: JMR, SDM, and YY, are inventors on patents describing inhibitors of 15-PGDH and their therapeutic uses. These include awarded US patents: 9790233, 9789116, 9801863, 10301320, 10420752, 10869871, 10945998, 11426420. These patents have been licensed to Rodeo Therapeutics, which is owned by Amgen. JMR and SDM are beneficiaries of founders stock in Rodeo, and serve as consultants to Amgen on topics related to 15-PGDH inhibition. All other authors declare no competing interests.